Premium
Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial ( EDI‐PIO ) in chronic myeloid leukemia with deep molecular response
Author(s) -
Pagnano Katia B.B.,
Lopes Ana Beatriz P.,
Miranda Eliana C.,
Delamain Márcia T.,
Duarte Gislaine O.,
Rodrigues Bruna R.V.,
Povoa Valquiria M.O.,
Furlin Graziele C.P.,
Vianna Jessica C.,
Silva Matheus A.S.,
De Souza Carmino A,
De Paula Erich V
Publication year - 2020
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.25986
Subject(s) - discontinuation , imatinib , myeloid leukemia , medicine , pioglitazone , leukemia , oncology , pharmacology , cancer research , endocrinology , type 2 diabetes , diabetes mellitus